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RAPID COMMUNICATION
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Depressed expression of calcium receptor in parathyroid gland tissue of
patients with hyperparathyroidism. The factors involved in abnormal
parathyroid cell secretory function and growth in patients with primary
(10) and secondary (110) hyperparathyroidism are still incompletely under-
stood. We compared the expression of the calcium-sensing receptor (CaR)
at the gene message and the protein level in parathyroid tissue obtained
from patients with 10 non-uremic or 110 uremic hyperparathyroidism with
that in normal parathyroid tissue, using in situ hybridization and immu-
nohistochemistry techniques. The expression of the CaR mRNA and
protein was reduced in most cases of JO adenoma and JJ0 hyperplasia,
compared with strong expression in normal parathyroid tissue. In 110
hyperparathyroidism, expression of both receptor mRNA message and
protein was often particularly depressed in nodular areas, compared with
adjacent non-nodular hyperplasia. Decreased Ca-R expression in adeno-
matous and hyperplastic parathyroid glands would be compatible with a
less efficient control of PTH synthesis and secretion by plasma calcium
than in normal parathyroid tissue.
Our understanding at the cellular and molecular levels of the
receptor-mediated effects of calcium and calcitriol on the pre-pro-
parathyroid hormone gene and the gene product, parathyroid
hormone (PTH), has substantially improved during recent years
[1]. However, the escape from physiologic control of the secretory
function and growth of parathyroid tissue in hyperparathyroid
disease states is still incompletely understood.
In secondary (110), reactive forms of hyperparathyroidism, low
plasma levels of calcium and/or calcitriol clearly play a major role
in stimulating PTH synthesis and secretion, and probably also in
enhancing parathyroid hyperplasia [21. An abnormally low expres-
sion of the vitamin D receptor (VDR) has been proposed as
another possible mechanism, which could he limited to areas of
nodular transformation [3]. VDR expression in primary (1°)
hyperparathyroidism has been examined in one study [41, hut no
comparison was made with normal parathyroid tissue. Whether
changes in the expression of the calcium-sensing receptor (CaR),
which recently has been cloned by Brown et al [5], occur in 1° or
110 hyperparathyroidism is unknown at present. Interestingly, the
expression of another calcium sensing protein (CAS), which
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belongs to the low-density-lipoprotein receptor superfamily [6],
has been found to be diminished in 10 hyperparathyroidism [71.
The purpose of the present study was to examine the expression
of the CaR gene message and protein in parathyroid tissue of
patients with J0 parathyroid adenoma and normal renal function
and in that of uremic patients with JJ0 hyperparathyroidism,
compared with expression in normal human parathyroid tissue.
The recognition of an abnormal CaR expression could help to
obtain a better insight into the mechanisms involved in abnormal
parathyroid secretory function and growth.
Methods
Patients
Normal parathyroid glands were obtained from 8 patients
during surgery for various thyroid diseases. Pathologic parathy-
roid gland tissue was sampled in 16 patients with J0 hyperpara-
thyroidism and normal renal function (all single adenomas) and in
13 patients with uremic 110 hyperparathyroidism (diffuse hyper-
plasia with or without nodule formations). Mean SEM ages were
58 4 and 45 6 years in patients with 10 and 110 hyperparathy-
roidism, respectively. Mean plasma total calcium levels were
2.87 0.09 and 2.55 0.06 m, and mean plasma phosphate
levels 0.79 0.05 and 2.47 1.5 ms, respectively. Mean plasma
immunoreactive PTHI-84 levels were elevated in all cases: 117
10 and 939 120 pg/mI, respectively (normal range 10 to 65
pg/mI). Uremie patients underwent intermittent hemodialysis
treatment for variable time periods (mean 5.2 1.2 years).
Tissue fragments were frozen after surgical removal and stored
at —80°C. Histopathologic examination by light microscopy was
routinely performed on each tissue sample using standard tech-
niques.
Oligonucleotide probes
Two calcium receptor (CaR) antisense 22-mer oligonucleotides
corresponding respectively to bases 2412 to 2433 (oligo 1; 5'-
YFGCGGAACTFGATGAAGACGC-3') and to bases 2928 to
2949 (oligo 2; 5'-ATGCTGAAGGTGATGAACTTGG-3') were
synthesized. The sequences were obtained from Gene Data Bank,
code gb/S67307 (NCE3I, Bethesda, MD, USA). Terminal trans-
ferase was used to label probes with digoxigenin-1i-dUTP and
dATP following manufacturer's recommendations (Boehringer,
Mannheim, Germany).
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In situ hybridization
Hybridization was performed using frozen sections from 4
patients with normal parathyroids, 6 patients with J0 hyperpara-
thyroidism and 4 patients with 110 hyperparathyroidism. In situ
hybridization was performed according to a previously described
method [8], with minor modifications. Briefly, 5 p-thick cryostat
sections were fixed in 4% paraformaldehyde-PBS for 10 minutes,
rinsed in PBS and prehybridized during one hour at room
temperature in a mixture containing 4 X SSC and 1% Denhard's
solution. Adjacent sections of each block were mounted on five
different slides. Two of them were treated with specific oligonu-
cleotide probes in two different assays, and the other three were
control slides.
Hybridization was carried out at 37°C for 16 hours in 50%
formamide, 1% Denhardt's solution, 15% SSC, 10 mg/mI yeast
transfer RNA, 10 mg/mI salmon sperm DNA and 4% Sarkosyl.
Each section was covered with 100 .d of the hybridization solution
containing 150 pmol/ml of the appropriate DIG-labeled antisense
oligonucleotide probe.
After hybridization, sections were washed two times in 2 X SSC
at room temperature, followed by two washes in I X SSC, one
wash in 0.5 X SSC and a final wash in 0.1 X SSC at 37°C during
30 minutes.
Sections were then equilibrated in buffer A (150 mivi NaCI, 100
mM Tris-HCI), supplemented with 2% of normal sheep serum and
0.3% of Triton X-100, at room temperature during one hour and
incubated overnight at 4°C with 1% of normal sheep serum, 0.3%
Triton X-100 and anti-DIG Fab-fragment—alkaline phosphatase
conjugate. After several washes the sections were incubated in
darkness during two hours in solution containing NBT (nitro blue
tetrazolium) and 5-bromo-4 chloro-3-indolyl phosphate (BCIP)
substrate. After developemerit, sections were washed in buffer and
mounted in Aquatex. Controls of the specificity of in situ hybrid-
ization findings were obtained as follows: (1) no signal after
preincubation in a solution containing 150 pg/mI of labeled probe
and 50-fold concentrated unlabeled oligonucleotide; (2) no signal
when omitting oligonucleotide probe; and (3) no signal after
RNAse pre-treatement of tissue sections.
Anti-CaR antibody
A polyclonal anti-CaR specific antibody was used that was
generated in rabbits with a fusion peptide (a GST fusion ex-
pressed in Escherichia coil) representing amino acids 340 to 620 of
the human CaR [9]. (The antiserum was kindly provided by
Edward Nemeth, M.D., NPS Pharmaceuticals, Salt Lake City,
USA).
Immunohistochemistty
For immunohistochemical staining a series of parathyroid tissue
fragments from 8 patients with normal parathyroids, 10 patients
with 1° hyperparathyroidism and ii patients with 11° hyperpara-
thyroidism were sectioned at 5 m in a cryostat and treated with
0.3% H202 in methanol for 20 minutes. After incubation in
blocking solution, the slides were exposed to the first antibody,
directed against the CaR, for 40 minutes in a humidified chamber
at room temperature. They were then rinsed and incubated with
a second antibody (peroxidase-conjugated goat antirabbit IgG)
for 30 minutes. Immunorcactivity was revealed using AEC kit
Table 1. Ca-sensing receptor mRNA expression, as evaluated by in situ
hybridization (ISH), in parathyroid tissue samples from patients with
normal parathyroid glands (normal), primary (1°) hyperparathyroidism,
and secondary (11°) hyperparathyroidism
11° hyperparathyroidism
(N =4)
Diffuse Nodular
Parathyroid
Tissue
Normal
(N = 4)
1° hyperparathyroidism(N = 6)
hyperplastic hyperplastic
area area
Number 14±3 5±1 11±3 7±3
of ISH
signals
Mean 52 4.9 15 0.7 22 8.4 21.5 7.7
optical
density
Data are mean SEM.
solution (Vector, Burlingame, VT, USA) The specificity of the
antibody has been assessed previously [9]. In addition, it was
ascertained in the present study by negative controls using pre-
immune rabbit serum.
Quantification of in situ hybridization and
immunohistochemical signals
Staining intensity of parathyroid tissue sections after treatment
by in situ hybridization and immunohistochemistry, respectively,
was evaluated by three independent observers. Three to four
sections per specimen were assayed. For immunohistochemistry,
the presence of perinuclear ring-shaped staining was evaluated for
each parathyroid cell, at a magnification x400, and the ratio of
positive to negative cells was established. A total number of
approximately 400 cells was counted for each tissue section. For in
situ hybridization, the number of colorimetric signals forming
patches per cell was counted on each tissue section, at a magni-
fication of X 1000. Hybridization signal numbers were then aver-
aged, and mean values calculated. In parallel, tissue sample
staining density was determined by a computer-based image
analysis software developed by one of us according to Mize,
Holdefer and Nabors [10] with minor modifications. Images were
grabbed using a Leica DMR microscope Leica (Leica, Germany)
and a monochrome Photometrics CCD camera (Photometrics,
USA). For each specimen, a minimum of three fields was mea-
sured. The mean optical density value for negative controls was
8.2 6.7. Checking of potential errors in image analysis was
performed by comparison of repeat measurements of the same
slide at different days, yielding a variation coefficient of 7%.
Statistical evaluation of results obtained was done using Stu-
dent's unpaired or paired t-test, as appropriate.
Results
Light microscopy analysis
In all cases of hyperparathyroidism studied, the diagnosis of
predominant chief cell adenoma or hyperplasia was confirmed by
histologic examination of paraffin-embedded tissue sections after
hematoxylin-eosin staining. The cellular arrangement showed a
variety of aspects including nodular, acinar, follicular and trahec-
ular patterns. Areas of oxyphil cells were detected in approxi-
mately one third of the adenomas studied. Nodular formations
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Fig. 1. Charactcrisiic feature of CaR mRNA expression by in situ hybridization in parathyroid tissue. (A) Normal parathyroid gland, (B) primary
hyperparathyroidism (solitary adenoma), and (C) secondary hyperparathyroidism (diffuse hyperplasia with nodule formation, uremic patient). The
strong staining pattern in (A) contrasts with extremely weak staining in (B) and moderate staining in (C). Note the relative decrease of CaR signal in
(C) in nodular area (right side), compared with that in adjacent, diffusely hyperplastic area (left side) and absence of signal over fibrous tissue. The
photomicrographs were taken at a magnification of x400.
mainly composed of chief cells were also observed in five of the Expression of CaR gene message
hyperplastic glands from uremic patients with Il hyperparathy- The hybridization signals, usually forming blue purple patches,
roidism. were mostly confined to the cytoplasm of the chief cells, while
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Fig. 1. Continued.
mesenchymal elements were not labeled. A strong expression of
CaR mRNA by in situ hybridization was observed in the 4 samples
of normal parathyroid tissue. In contrast, CaR mRNA expression
was markedly decreased in the 6 samples of adenomatous tissue of
patients with 10 hyperparathyroidism. Expression was also de-
creased in the 4 samples of parathyroid tissue of uremic patients
with severe 110 hyperparathyroidism. Overall differences in
mRNA expression are shown in Table 1, as evaluated by either
counting numbers of hybridization signals or by computer-assisted
image analysis. In some instances, the decrease was more pro-
nounced in nodular areas than in surrounding areas of diffuse
hyperplasia using light microscopy. However, such a difference
was not found using image analysis. Figure 1 shows a typical
pattern for each patient category, with a nodular and diffuse
hyperplastic area in the tissue from a patient with 110 hyperpara-
thyroidism.
Expression of CaR protein
CaR protein immunostaining was mainly limited to the area of
membrane and cytoplasm in parathyroid cells of all tissue samples
examined. A strong CaR staining was detected in the 8 samples of
normal parathyroid tissue, whereas staining intensity was mark-
edly diminished in most cases of J0 and 110 hyperparathyroidism.
Quantative differences in CaR protein staining are shown in
Figure 2. For 110 hyperparathyroidism samples, tissue areas were
analyzed as a whole, including diffuse hyperplasia and nodular
structures. However, since staining intensity often was lower at
weak magnification in well-circumscribed nodular areas in only 5
tissue samples, we then analyzed those areas separately from
diffusely hyperplastic areas. The nodular formations in hyperplas-
tic glands from 110 hyperparathyroidism patients exhibited a
particularly weak staining of CaR, as shown in Figure 3. Cells
composing vessel walls, perivascular stroma and capsular fibrous
tissue stained negative for the CaR protein. Figure 4 shows a
characteristic feature for each type of tissue.
Discussion
The present study demonstrates a decrease of parathyroid CaR
mRNA expression, based on an in situ hybridization technique, in
both J0 and JJ0 hyperparathyroidism as compared to normal
parathyroid tissue. Our study further shows that the decrease is
not limited to the gene message, but that it is present, in both
types of disease, at the receptor protein level as well. The decrease
of CaR protein expression was particularly pronounced in nodular
areas of hyperplastic glands from uremic patients with 110 hyper-
parathyroidism.
Mutations of the CaR gene are associated with abnormal PTH
secretion, and different mutations may he associated either with
hyperparathyroidism [11] or hypoparathyroidism [12]. The full
knock-out of the CaR gene in a mouse model was shown to induce
a picture comparable to that of severe neonatal hyperparathyroid-
ism [13]. Recently, loss of heterozygosity for genetic markers
flanking the CaR gene locus has been found in a small number of
patients with 1° hyperparathyroidism in one series [14], whereas in
another series no evidence was found for somatic mutations of the
CaR gene [15]. l-lowever, several gene transcripts of different sizes
have been observed in a parathyroid adenoma, in addition to the
main transcript of 5.4 kilohases [161.
Our demonstration of a diminished expression of the CaR gene
message and its protein product in hyperplastic parathyroid tissue
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Fig. 2. Histogram of CaR protein expression by
immunohistochemistiy, expressed as percent
positive cells of total number of cells examined, in
parathyroid tissue from patients with normal
parathyroid glands, 1° hyperparathyroidism
(solitaiy adenoma), and 110 hypeiparathyroidism.
Fig. 3. Histogram of CaR protein expression by
immunohistochemistry, expressed as percent
positive cells of total number of cells examined, in
parathyroid tissue fro,n patients with normal
parathyroid glands and from patients with fl0
hyperparathyroidism in whom two subsets of
parathyroid glands have been analyzed separately,
namely diffuse liypeiplasia with nodule Jhrmalion
and diffuse hyperplasia without nodule formation.
could explain observations of an abnormal sensing of the extra- patient heterogeneity and differences in disease severity may
cellular calcium concentration. A previous in vitro study showed a explain these apparently discrepant observations [21, 22].
shift in the relationship between ionized calcium and PTH The present finding of a decreased CaR expression in chronic
secretion in parathyroid glands sampled from patients with 10or dialysis patients is in apparent contradiction with a recent report
110 hyperparathyroidism [17]. Similarly, abnormal calcium sensing of no change of CaR expression in rats with chronic renal failure
by the parathyroids has been described in such patients in vivo [18, 1231. Differences in the degree of renal failure and the duration
19], even though not all authors would agree, at least for uremic and degree of 110 hyperparathyroidism might account for this
patients with severe 110 hyperparathyroidism [20]. Patient-to- discrepancy.
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Fig. 4. CaR protein expression by immunohistochemistiy in parathyroid tissue from (A) normal parathyroid gland, (B) r hypeparathyroidism, and (C) JJO
uremic hyperparathyroidism (diffuse hypeiplasia). The strong staining pattern in (A) contrasts with weaker staining in (B) and extremely weak staining
in (C). The photomicrographs were taken at a magnification of X400.
The staining intensity of the CaR protein in normal parathyroid in the cell membrane. In contrast, the staining intensity was
tissue was strong and the cellular staining pattern was ring- generally weak in pathologic tissue from patients with J0 and Jj0
shaped, possibly corresponding to predominant receptor location hyperparathyroidism and the expression pattern was more diffuse
a-p
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Fig. 4. Continued.
accross the cytoplasm, instead of a predilection for the cell
membrane. The reason for the decrease in the CaR mRNA and
protein expression in hyperplastic parathyroid tissue is not clear at
present. The factors regulating CaR expression have not yet been
identified. Whereas calcium does not appear to be directly
involved [23] a potentially regulatory role of calcitriol is presently
under debate [23, 24]. It is also possible that modulation of CaR
biosynthesis occurs through alternative RNA processing [161.
A down-regulation of the receptor for the other major modu-
lator of parathyroid function, namely calcitriol, was first shown
several years ago in the parathyroid tissue of patients with 110
hyperparathyroidism, using a vitamin D binding technique, com-
pared with its expression in I' hyperparathyroidism [41. However,
no normal parathyroid tissue was examined for comparison. This
finding has been subsequently questioned [25]. More recently,
decreased VDR protein expression has been shown to occur in
nodular areas of parathyroid glands in uremic patients with severe
110 hyperparathyroidism, but not in diffusely hyperplastic areas [3].
Again, normal parathyroid tissue was not available. In preliminary
studies, we found a marked down-regulation of VDR mRNA
expression in parathyroid tissue of patients with 10 and 11°
hyperparathyroidisni, compared with normal tissue [26].
The findings of a particularly marked down-regulation of the
CaR and the VDR in nodular areas of parathyroid tissue from
patients with JJ0 hyperparathyroidism would be compatible with
an abnormal regulation of receptor expression, perhaps associ-
ated with an autonomous growth pattern, although in our expe-
rience no good correlation existed between the clonal type of
parathyroid tissue growth and the histologic finding of a nodular
or diffusely hyperplastic growth [271.
To date, the question remains largely unsolved of whether the
excessive PTH production characteristic of various hyperparathy-
roid states is mainly due to an unopposed increase of PTH
synthesis and/or secretion at the cellular level, or if it is mainly due
to an increase in parathyroid cell mass, in the absence of excessive
PTH synthesis per cell [28]. The former hypothesis would be
compatible with a pathologic regulation of PTH production at the
cellular level by factors normally involved in its control such as
calcium and calcitriol. The latter hypothesis could imply a dis-
turbed local or systemic regulation by other factors involved in cell
growth and viability, in addition to calcium and calcitriol. Re-
cently, Naveh-Many et a! [29] have shown in rat studies that
calcium and phosphate are important independent actors in the
control of parathyroid cell growth. Whereas a phosphate-poor
diet depressed cell proliferation, a diet rich in phosphate or poor
in calcium stimulated it markedly. This was true for rats with
normal renal function as well as for uremic rats. A decrease in
CaR expression would be able to potentiate the effect of calcium
deficiency. Other factors arc potentially involved in enhanced cell
proliferation. We have observed an increased expression of
transforming growth factor-u (TGF-a) mRNA and protein in the
parathyroid tissue of uremic patients with severe 11° hyperpara-
thyroidism [30]. Obviously, the two hypotheses are not mutually
exclusive.
The excessive PTH secretion of primary (1°) parathyroid ade-
noma has been shown to be associated with uncontrolled para-
thyroid cell growth which is monoclonal in nature [31]. The
PRAD1/cyclin DI oncogene, which is abnormally placed under the
influence of the regulatory region of the PTH gene, could be
responsible in at least a subgroup of patients with 10 adenoma [32].
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More unexpectedly, sporadic, diffuse 1° parathyroid hyperplasia
and even the 110 parathyroid hyperplasia of chronic renal failure
recently have been shown by us to often exhibit a monoclonal
growth pattern [27]. Possible underlying somatic mutations of
specific suppressor or enhancer genes await elucidation. Whether
underlying mutations or deletions of the CaR gene or changes in
RNA processing are involved remains to be seen. Mutations of
the gene, if any, do not appear to be frequently involved [33]. To
our knowledge, the possibility of a somatic mutation of the VDR
gene has not yet been addressed. Interestingly, a greater preva-
lence of the VDR genotype bb recently has been found in
postmenopausal women with 10 hyperparathyroidism than in
appropriate female control subjects [34].
Since the submission of our article, Kifor et a! [35] have
published a paper reporting a decrease in CaR protein expression
in parathyroid tissue from patients with 10 as well as with 110
hyperparathyroidism, identical to our finding. However, they used
biopsies of nori-adenomatous, probably functionally less-active
parathyroid glands obtained from their patients with I" hyperpara-
thyroidism, whereas we used normal parathyroid glands obtained
from patients operated upon for thyroid disease. In addition, the
present study provides evidence that the decrease of CaR expres-
sion also occurs at the gene message level in both 10 and JJ0
hyperparathyroidism.
In conclusion, the present finding of a decreased expression of
the CaR gene message and protein in the hyperplastic parathyroid
tissue of non-uremic patients with 1° and of uremic patients with
110 hyperparathyroidism provides a better insight into the abnor-
mal regulation of the endocrine function and growth of this tissue.
The down-regulation of the CaR receptor could play an important
role in the abnormal secretory and growth patterns of parathyroid
glands in these pathologies. A better understanding of the under-
lying abnormalities should lead to a more appropriate clinical
management.
Reprint requests to Ti/man B. Drüeke, M.D., INSERM Unite 90, Hôpital
Necker, /61 rue de Sèvres, 75743 Paris Cedex 15, France.
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